RegenXBio (RGNX) Stock Statistics & Valuation Metrics

RegenXBio has a market cap or net worth of $409.17M. The enterprise value is $371.07M.

RegenXBio has 50,514,217 shares outstanding. The number of shares has decreased by -2.65% in one year.

RegenXBio’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -61.63%.

The current PE Ratio of RegenXBio is ―. RegenXBio’s PEG ratio is ―.

In the last 12 months, RegenXBio had revenue of 83.33M and earned -227.10M in profits. Earnings per share was -4.59.

In the last 12 months, operating cash flow was -87.89M and capital expenditures -2.82M, giving a free cash flow of -90.71M billion.

RegenXBio pays an annual dividend of ―, resulting in a dividend yield of ―

RegenXBio upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).

RegenXBio as a current ratio of 2.69, with Debt / Equity ratio of 127.15%

In the past 12 months, RegenXBio has paid 0.00 in taxes.

RegenXBio EV to EBITDA ratio is -2.05, with an EV/FCF ratio of -2.32.

RegenXBio has $323.30M in cash and marketable securities with $271.69M in debt, giving a net cash position of -$51.61M billion.

Gross margin is 79.94%, with operating margin of -280.03%, and net profit margin of -272.54%.

The average price target for RegenXBio is $25.22, which is 11.43% higher than the current price. The consensus rating is Strong Buy